Evidence map›Paper›PMID 38155905›Full record

ArticleFrontiers in pharmacology2023

PGF

Isabel Hamshaw, Anne Straube, Richard Stark, Laura Baxter, Mohammad T Alam, Walter J Wever, Jun Yin, Yong Yue, Philippe Pinton, Aritro Sen and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Isabel HamshawClinical Science Research Laboratories, Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry, United Kingdom.
Anne StraubeCentre for Mechanochemical Cell Biology, Division of Biomedical Sciences, University of Warwick, Coventry, United Kingdom.
Richard StarkBioinformatics RTP, Warwick Medical School, University of Warwick, Coventry, United Kingdom.
Laura BaxterBioinformatics RTP, Warwick Medical School, University of Warwick, Coventry, United Kingdom.
Mohammad T AlamBioinformatics RTP, Warwick Medical School, University of Warwick, Coventry, United Kingdom.
Walter J WeverFerring Research Institute Inc., San Diego, United Kingdom.
Jun YinFerring Research Institute Inc., San Diego, United Kingdom.
Yong YueFerring Research Institute Inc., San Diego, United Kingdom.
Philippe PintonFerring Research Institute Inc., San Diego, United Kingdom.
Aritro SenFerring Research Institute Inc., San Diego, United Kingdom.
Gregory D FergusonFerring Research Institute Inc., San Diego, United Kingdom.
Andrew M BlanksClinical Science Research Laboratories, Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry, United Kingdom.
University of Warwick · GBFerring Pharmaceuticals (United Kingdom) · GBFerring Pharmaceuticals (Denmark) · DK

Funding

Wellcome Trust
6 · The paper itself

Abstract

Preterm birth is the leading cause of infant morbidity and mortality. There has been an interest in developing prostaglandin F

Indexed as

FP antagonistsFP receptorlabourmyometriumPGF2αpreterm birthsmooth muscle

Identifiers

PMID38155905
PMCPMC10752971
OpenAlexW4389743062

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.